Literature DB >> 20890624

Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis.

Cristina Guijarro1, Julián Benito-León, Félix Bermejo-Pareja.   

Abstract

We describe two multiple sclerosis patients who displayed widespread urticaria due to intramuscular interferon beta-1a (INF-β-1a). Clinicians should be aware of this adverse event, since it may be severe and it may lead to the definitive interruption of treatment. Widespread urticaria complicating intramuscular INF-β-1a therapy in multiple sclerosis should be therefore added to the list of dermatological lesions associated with interferon therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890624     DOI: 10.1007/s10072-010-0432-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  9 in total

1.  An urticarial IgE-mediated reaction to interferon beta-1b.

Authors:  D L Brown; I S Login; L Borish; P L Powers
Journal:  Neurology       Date:  2001-05-22       Impact factor: 9.910

Review 2.  Drug-induced urticaria.

Authors:  F Cousin; K Philips; B Favier; J Bienvenu; J F Nicolas
Journal:  Eur J Dermatol       Date:  2001 May-Jun       Impact factor: 3.328

3.  Severe urticaria due to recombinant interferon beta-1a.

Authors:  L Mazzeo; L Ricciardi; M C Fazio; O Fogliani; R Fedele; E Ferlazzo; S Isola
Journal:  Br J Dermatol       Date:  2003-01       Impact factor: 9.302

4.  Interleukin-12 suppresses immunoglobulin E production but enhances immunoglobulin G4 production by human peripheral blood mononuclear cells.

Authors:  B A de Boer; Y C Kruize; P J Rotmans; M Yazdanbakhsh
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

5.  Severe anaphylaxis with recombinant interferon beta.

Authors:  T Corona; C Leon; L Ostrosky-Zeichner
Journal:  Neurology       Date:  1999-01-15       Impact factor: 9.910

6.  Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

Authors:  J A Cohen; M Rovaris; A D Goodman; D Ladkani; D Wynn; M Filippi
Journal:  Neurology       Date:  2007-03-20       Impact factor: 9.910

Review 7.  Multiple sclerosis: side effects of interferon beta therapy and their management.

Authors:  E U Walther; R Hohlfeld
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

8.  Desensitization in interferon-beta1a allergy: a case report.

Authors:  Ayse Fusun Kalpaklioglu; Ayse Baccioglu Kavut; Ali Kemal Erdemoglu
Journal:  Int Arch Allergy Immunol       Date:  2009-01-06       Impact factor: 2.749

9.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

  9 in total
  2 in total

Review 1.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

Review 2.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.